Boston Scientific (NYSE:BSX) Price Target Lowered to $100.00 at Barclays

Boston Scientific (NYSE:BSX) had its price objective lowered by analysts at Barclays from $124.00 to $100.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical equipment provider’s stock. Barclays‘s price target would indicate a potential upside of 58.29% from the stock’s current price.

BSX has been the subject of several other reports. Canaccord Genuity Group reduced their target price on Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Argus raised Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $115.00 target price on shares of Boston Scientific in a research report on Monday, March 30th. TD Cowen reduced their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Finally, Robert W. Baird decreased their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $101.50.

Boston Scientific Trading Up 6.1%

NYSE BSX opened at $63.18 on Wednesday. The firm has a market capitalization of $93.89 billion, a PE ratio of 32.28, a price-to-earnings-growth ratio of 0.94 and a beta of 0.78. The business’s 50-day moving average price is $69.04 and its two-hundred day moving average price is $86.31. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific has a 12 month low of $59.38 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the firm earned $0.75 earnings per share. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts expect that Boston Scientific will post 3.45 EPS for the current year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.34% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

Several hedge funds and other institutional investors have recently modified their holdings of BSX. Cambient Family Office LLC boosted its position in shares of Boston Scientific by 30.1% in the first quarter. Cambient Family Office LLC now owns 3,699 shares of the medical equipment provider’s stock valued at $232,000 after acquiring an additional 855 shares during the period. Pinnacle Wealth Management Advisory Group LLC raised its position in Boston Scientific by 56.9% during the first quarter. Pinnacle Wealth Management Advisory Group LLC now owns 8,452 shares of the medical equipment provider’s stock valued at $530,000 after purchasing an additional 3,065 shares in the last quarter. VCI Wealth Management LLC boosted its holdings in shares of Boston Scientific by 55.2% in the 1st quarter. VCI Wealth Management LLC now owns 24,261 shares of the medical equipment provider’s stock worth $1,522,000 after purchasing an additional 8,632 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its position in shares of Boston Scientific by 72.7% during the 1st quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 38,000 shares of the medical equipment provider’s stock valued at $2,384,000 after purchasing an additional 16,000 shares during the last quarter. Finally, OLD National Bancorp IN lifted its position in Boston Scientific by 193.0% in the 1st quarter. OLD National Bancorp IN now owns 6,320 shares of the medical equipment provider’s stock worth $397,000 after buying an additional 4,163 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results showed durable topline growth and a small EPS beat: net sales of $5.203B (up ~11.6% year/year) and adjusted EPS $0.80, slightly above consensus; GAAP net income rose sharply year over year — a signal that demand for core devices remains solid. Boston Scientific announces results for first quarter 2026
• Neutral Sentiment: Several sell?side firms have adjusted models/price targets but many still rate BSX a Buy — analysts view the guidance cut as a potential reset that creates longer?term upside if execution rebounds. Boston Scientific Stock Is Trending Today: What To Know Now
• Neutral Sentiment: Unusually high options activity (large call purchases) and elevated trading volume ahead of the print indicate traders positioned for volatility rather than a clear directional conviction; this can amplify intraday moves.
• Negative Sentiment: Management cut FY?2026 and Q2 guidance: FY EPS guide of $3.340–3.410 vs. ~3.45 consensus and Q2 EPS guide of $0.820–0.840 vs. ~0.86 consensus; revenue outlook was lowered as well — the guidance miss/trim is the primary near?term negative catalyst. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Multiple securities class?action filings and investor?notice campaigns (several law firms seeking lead plaintiffs; May 4 deadline) add headline/legal risk and can pressure sentiment and float until resolved. BSX Investor Alert: Securities Fraud Lawsuit
• Negative Sentiment: Recent reports of meaningful insider and institutional selling, plus prior analyst downgrades/target trims, increase near?term supply pressure and reduce confidence until management demonstrates rehabbed guidance/trajectory.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.